Cairo Pharmaceuticals results, Q2 2022
Net profit, assets, equity and cash flow for Q2 2022, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit50.75 millionEGP
Total assets1.21 billionEGP
Shareholders' equity710 millionEGP
Operating cash flow905 thousandEGP
In short
- Cairo Pharmaceuticals's net profit for Q2 2022 was about 50.75 million EGP.
- Total assets at the end of Q2 2022 were about 1.21 billion EGP, and shareholders' equity about 710 million EGP.
- Operating cash flow for Q2 2022 was positive at 905 thousand EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit50.75 million——
Gross profit95.54 million——
Total assets1.21 billion——
Total liabilities498 million——
Shareholders' equity710 million——
Total liabilities and equity1.21 billion——
Operating cash flow905 thousand——
Investing cash flow-12.57 million——
Financing cash flow-52.69 million——
Net change in cash-64.35 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Cairo Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy